Management of Hypertension in Patients with Supraventricular Tachycardia
Pharmacological Management
- The American College of Cardiology recommends ACE inhibitors and ARBs, like losartan, as Class I, Level of Evidence A/B for hypertension management, particularly in patients with anterior MI, LV dysfunction, heart failure, or diabetes 3
- The American Heart Association suggests that the target blood pressure in patients with hypertension and ischemic heart disease is <130/80 mm Hg, though caution is advised when diastolic blood pressure falls below 60 mm Hg 3
- Unlike calcium channel blockers or beta-blockers, losartan does not interact with the electrical pathways involved in supraventricular tachycardia, as it works by blocking the AT1 receptor subtype 1, 2
- For acute SVT management, first-line treatment includes vagal maneuvers, followed by adenosine (95% effective for AVNRT), or intravenous calcium channel blockers (diltiazem/verapamil with 64-98% success rates), according to the American Heart Association 2
- Beta-blockers and calcium channel blockers work by affecting AV nodal conduction, which is the mechanism by which most SVTs (AVNRT, AVRT) are terminated or prevented, as stated by the American College of Cardiology 1, 2